Johnson & Johnson (NYSE: JNJ) announced that its experimental drug nipocalimab met the primary endpoint in a Phase 2 study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE